Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Oligoscience Biotechnology GmbH has 1 pending office action in Biotechnology & Pharmaceuticals. The matter is associated with 1 distinct examiner and 1 distinct art unit, giving the prosecution record a single assignment structure.
OLSON, ANDREA STEFFEL is the busiest examiner, with 1 pending matter. The immediate practical task is to address that examiner's issues within the applicable biotechnology and pharmaceutical examination context.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| OLSON, ANDREA STEFFEL | 1 | 62.5% | -11.9% |
| Art Unit | Apps |
|---|---|
| 1693 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17130195 | USE OF HUMAN MILK OLIGOSACCHARIDES IN CALVES FATTENING | OLSON, ANDREA STEFFEL | 1693 | §103 | Final Rejection | 36d | Pending | Dec 22, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialOligoscience Biotechnology GmbH has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Andrea Steffel Olson has the most, with 1 of Oligoscience Biotechnology GmbH's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.